DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a…
MILAN, July 17, 2025 /PRNewswire/ -- A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination…
Five and 10-year net annualized returns of 10.6% and 8.2%.$31.9 billion in cumulative net investment gains above the Reference Portfolio…
New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions, broadening access and driving national…